EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study

Koji Izutsu, Kiyoshi Ando, Momoko Nishikori, Hirohiko Shibayama, Hideki Goto, Junya Kuroda, Koji Kato, Yoshitaka Imaizumi, Kisato Nosaka, Rika Sakai, Maho Abe, Seiichiro Hojo und 2 weitere

International Journal of Hematology · 2024

DOI: 10.1007/s12185-024-03834-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Koji Izutsu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. kizutsu@ncc.go.jp. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Morpholines, Mutation, Pyridones. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eisai Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previously, we reported the efficacy and safety of tazemetostat in Japanese patients with relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) harboring the EZH2 mutation in a multicenter, open-label, phase II study. Here, we present a follow-up analysis of tazemetostat at a long-term median follow-up of 35.0 months. Twenty patients were enrolled: 17 in the FL cohort and three in the DLBCL cohort. In the FL cohort, the objective response rate was 70.6%, consistent with the primary analysis, and the median progression-free survival (PFS) was not reached. The 24-month and 36-month PFS rates were 72.1% (95% confidence interval [CI] 41.5%–88.6%) and 64.1% (95% CI 33.7%–83.4%), respectively. The median duration of treatment was 30.2 months. After the primary analysis at a median follow-up of 12.9 months, grade 1–2 urinary tract infection, peripheral motor neuropathy, and hypogammaglobulinemia newly emerged, but the incidence of adverse events (AEs) did not increase notably during this follow-up period. No unexpected grade ≥ 3 treatment-related AEs were reported. Long-term oral monotherapy with tazemetostat showed favorable efficacy and safety profiles, indicating that it may be a useful third-line or later treatment option for patients with relapsed/refractory FL harboring the EZH2 mutation. Trial registration: ClinicalTrials.gov: NCT03456726.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinMorpholinesMutationPyridonesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedBenzamidesBiphenyl CompoundsFollow-Up StudiesJapanLymphoma, FollicularLymphoma, Large B-Cell, DiffuseRecurrenceTreatment OutcomeClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

EZH2 mutationB-cell non-Hodgkin lymphomaPhase IITazemetostatTrimethylation of lysine 27 in histone 3

Substanzen

BenzamidesBiphenyl CompoundsEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanMorpholinesPyridonestazemetostat

Autor:innen und Institutionen

  • Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. kizutsu@ncc.go.jp.
  • Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
  • Department of Hematology and Oncology, Kyoto University, Kyoto, Japan.
  • Department of Hematology and Oncology, Osaka University Hospital, Suita, Japan.
  • Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.
  • Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Förderung

  • Eisai Co., Ltd.

Zitieren

APA

Izutsu, K., Ando, K., Nishikori, M., Shibayama, H., Goto, H., Kuroda, J., Kato, K., Imaizumi, Y., Nosaka, K., Sakai, R., Abe, M., Hojo, S., Nakanishi, T., & Rai, S. (2024). Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03834-9

Vancouver

Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, et al. Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03834-9

BibTeX
@article{Izutsu2024,
  author = {Izutsu, Koji and Ando, Kiyoshi and Nishikori, Momoko and Shibayama, Hirohiko and Goto, Hideki and Kuroda, Junya and Kato, Koji and Imaizumi, Yoshitaka and Nosaka, Kisato and Sakai, Rika and Abe, Maho and Hojo, Seiichiro and Nakanishi, Tadashi and Rai, Shinya},
  title = {Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study},
  journal = {International Journal of Hematology},
  year = {2024},
  doi = {10.1007/s12185-024-03834-9}
}
Kostenlos starten →